MA40403A - Méthodes de traitement de paramyxovirus - Google Patents

Méthodes de traitement de paramyxovirus

Info

Publication number
MA40403A
MA40403A MA040403A MA40403A MA40403A MA 40403 A MA40403 A MA 40403A MA 040403 A MA040403 A MA 040403A MA 40403 A MA40403 A MA 40403A MA 40403 A MA40403 A MA 40403A
Authority
MA
Morocco
Prior art keywords
treating
methods
paramyxoviruses
methylpropanoate
cytidine
Prior art date
Application number
MA040403A
Other languages
English (en)
Inventor
Lawrence M Blatt
Sushmita Mukherjee Chanda
John Fry
Qingling Zhang
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of MA40403A publication Critical patent/MA40403A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des procédés pour l'amélioration et/ou le traitement d'une infection à paramyxovirus, ou l'inhibition de la réplication d'un paramyxovirus, par l'utilisation de 3',5'-(2-méthylpropanoate-4'-c-(chlorométhyl)-2'-désoxy-2'-fluoro-cytidine (composé a)), le composé (a) ou son sel pharmaceutiquement acceptable pouvant fournir 4'-c-chlorométhyl-2'-désoxy-2'-fluoro-5'- (tétrahydrogène triphosphate)-cytidine ou son sel pharmaceutiquement acceptable (composé (b)).
MA040403A 2014-07-22 2015-07-20 Méthodes de traitement de paramyxovirus MA40403A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462027719P 2014-07-22 2014-07-22

Publications (1)

Publication Number Publication Date
MA40403A true MA40403A (fr) 2017-05-31

Family

ID=55163588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040403A MA40403A (fr) 2014-07-22 2015-07-20 Méthodes de traitement de paramyxovirus

Country Status (13)

Country Link
US (1) US20160022724A1 (fr)
EP (1) EP3171878A4 (fr)
JP (1) JP2017525681A (fr)
KR (1) KR20170031231A (fr)
AU (1) AU2015294343A1 (fr)
BR (1) BR112017001162A2 (fr)
CA (1) CA2955604A1 (fr)
CL (1) CL2017000156A1 (fr)
MA (1) MA40403A (fr)
MX (1) MX2017000983A (fr)
RU (1) RU2017105470A (fr)
TW (1) TW201609104A (fr)
WO (1) WO2016014398A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
CA2908313A1 (fr) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Traitement contre une infection par le virus de l'hepatite c utilisant une combinaison de composes
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
WO2015054465A1 (fr) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Nucléosides substitués, nucléotides substitués et analogues de ceux-ci
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
PE20170673A1 (es) * 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
WO2016069489A1 (fr) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Procédés de préparation d'analogues de nucléosides substitués
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US20180117042A1 (en) * 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
WO2018222774A1 (fr) * 2017-05-30 2018-12-06 Alios Biopharma, Inc. Méthodes de traitement des pneumovirus
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320444T1 (de) * 1991-08-26 2006-04-15 Scripps Research Inst Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
JPH0859508A (ja) * 1994-08-16 1996-03-05 Teijin Ltd サイトメガロウイルス網膜炎予防または治療剤
PT3012258T (pt) * 2010-06-24 2018-12-14 Gilead Sciences Inc Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral
SG10201913554YA (en) * 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
GEP201706721B (en) * 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
MX2017000983A (es) 2017-09-01
CA2955604A1 (fr) 2016-01-28
JP2017525681A (ja) 2017-09-07
KR20170031231A (ko) 2017-03-20
WO2016014398A1 (fr) 2016-01-28
EP3171878A1 (fr) 2017-05-31
TW201609104A (zh) 2016-03-16
AU2015294343A1 (en) 2017-02-02
BR112017001162A2 (pt) 2017-11-14
EP3171878A4 (fr) 2018-03-14
RU2017105470A (ru) 2018-08-22
US20160022724A1 (en) 2016-01-28
CL2017000156A1 (es) 2017-11-03
RU2017105470A3 (fr) 2019-02-28

Similar Documents

Publication Publication Date Title
MA40403A (fr) Méthodes de traitement de paramyxovirus
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
IL276883A (en) "Compositions, devices, systems, kits and methods for treating skin conditions"
IL283096A (en) Medical tool positioning devices, systems, and methods of use and manufacture
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
WO2016044556A3 (fr) Inhibiteurs d'arginine méthyltransférase et leurs utilisations
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
EP3212658A4 (fr) Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
HUE043553T2 (hu) Spiroindolin vegyületek a légúti óriás sejtes vírusfertõzés (RSV) kezeléséhez és megelõzéséhez
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2017013047A (es) Tratamiento de dolor.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
EP3253312A4 (fr) Plaques osseuses, systèmes et procédés d'utilisation
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
MX2019005504A (es) Potenciadores de bmp.
EP3269369A4 (fr) Agent de traitement d'une infection respiratoire
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MY186775A (en) Antibacterial compositions and methods
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
HK1231714A1 (en) Skin-referencing surgical guides
HK1263210A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)